{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:40:58Z","timestamp":1794487258669,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r\/r T-ALL), in a previous phase I trial report, at a median follow-up of 6.3\u00a0months. Here we report long-term safety and activity of the therapy after a 2-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants received CD7-directed CAR T cells derived from prior stem cell transplantation (SCT) donors or from HLA-matched new donors after lymphodepletion. The\u00a0target dose was 1\u2009\u00d7\u200910\n                      <jats:sup>6<\/jats:sup>\n                      (\u00b1\u200930%) CAR T cells per kg of patient weight. The primary endpoint was safety with efficacy secondary. This report focuses on the long-term follow-up and discusses them in the context of previously reported early outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty participants were enrolled and received infusion with CD7 CAR T cells. After a median follow-up time of 27.0 (range, 24.0\u201329.3) months, the overall response rate and complete response rate were 95% (19\/20 patients) and 85% (17\/20 patients), respectively, and 35% (7\/20) of patients proceeded to SCT. Six patients experienced disease relapse with a median time-to-relapse of 6 (range, 4.0\u201310.9) months, and 4 of these 6 patients were found to have lost CD7 expression on tumor cells. Progression-free survival (PFS) and overall survival (OS) rates 24\u00a0months after treatment were respectively 36.8% (95% CI, 13.8\u201359.8%) and 42.3% (95% CI, 18.8\u201365.8%), with median PFS and OS of respectively 11.0 (95% CI, 6.7\u201312.5) months and 18.3 (95% CI, 12.5\u201320.8) months. Previously reported short-term adverse events (&lt;\u200930\u00a0days after treatment) included grade 3\u20134 cytokine release syndrome (CRS;\u00a010%) and grade 1\u20132 graft-versus-host disease (GVHD; 60%). Serious adverse events reported\u2009&gt;\u200930\u00a0days after treatment included five infections and one grade 4 intestinal GVHD. Despite good CD7 CAR T-cell persistence, non-CAR T and natural killer cells were predominantly CD7-negative and eventually returned to normal levels in about half of the participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this 2-year follow-up analysis, donor-derived CD7 CAR T-cell treatment demonstrated durable efficacy in a subset of patients with r\/r T-ALL. Disease relapse was the main cause of treatment failure, and severe infection was a noteworthy late-onset adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Trial registration<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>ChiCTR2000034762.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-023-01427-3","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T07:02:59Z","timestamp":1680678179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"16","author":[{"given":"Yue","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuixiu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiecheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"3","key":"1427_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20(3):142\u201354.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1427_CR2","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114(25):5136\u201345.","journal-title":"Blood"},{"issue":"4","key":"1427_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/leu.2013.312","volume":"28","author":"P Jain","year":"2014","unstructured":"Jain P, Kantarjian H, Ravandi F, Thomas D, O\u2019Brien S, Kadia T, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014;28(4):973\u20135.","journal-title":"Leukemia"},{"issue":"1","key":"1427_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","volume":"18","author":"P Brown","year":"2020","unstructured":"Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18(1):81\u2013112.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"1427_CR5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O\u2019Brien S, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216\u201330.","journal-title":"Cancer"},{"issue":"9","key":"1427_CR6","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","volume":"21","author":"E Tavernier","year":"2007","unstructured":"Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907\u201314.","journal-title":"Leukemia"},{"issue":"3","key":"1427_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood"},{"issue":"4","key":"1427_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol A, Vives S, Hern\u00e1ndez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589\u201396.","journal-title":"Haematologica"},{"issue":"10","key":"1427_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341.","journal-title":"Blood"},{"issue":"6","key":"1427_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","volume":"26","author":"A Spyridonidis","year":"2012","unstructured":"Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211\u20137.","journal-title":"Leukemia"},{"issue":"7","key":"1427_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","volume":"19","author":"LM Poon","year":"2013","unstructured":"Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1059\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"1427_CR12","doi-asserted-by":"publisher","first-page":"7685","DOI":"10.3390\/ijms21207685","volume":"21","author":"F Bay\u00f3n-Calder\u00f3n","year":"2020","unstructured":"Bay\u00f3n-Calder\u00f3n F, Toribio ML, Gonz\u00e1lez-Garc\u00eda S. Facts and Challenges in Immunotherapy for T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2020;21(20):7685.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1427_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"25","key":"1427_CR14","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, et al. Engineering naturally occurring CD7-T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684\u201396.","journal-title":"Blood"},{"issue":"6","key":"1427_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140(6):619\u201329.","journal-title":"Blood"},{"issue":"30","key":"1427_CR16","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39(30):3340\u201351.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1427_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1427_CR18","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825\u20138. PMID: 7581076.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"1427_CR19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"1427_CR20","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","volume":"6","author":"K Mullanfiroze","year":"2022","unstructured":"Mullanfiroze K, Lazareva A, Chu J, Williams L, Burridge S, Silva J, et al. CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. Blood Adv. 2022;6(16):4715\u20138.","journal-title":"Blood Adv"},{"issue":"12","key":"1427_CR21","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ajh.25957","volume":"95","author":"A Candoni","year":"2020","unstructured":"Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020;95(12):1466\u201372.","journal-title":"Am J Hematol"},{"issue":"10","key":"1427_CR22","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"1427_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","volume":"12","author":"T Rabilloud","year":"2021","unstructured":"Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun. 2021;12(1):865.","journal-title":"Nat Commun"},{"issue":"13","key":"1427_CR24","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin Cancer Res. 2022;28(13):2830\u201343.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1427_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007.","journal-title":"Cell Res"},{"issue":"4","key":"1427_CR26","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140(4):321\u201334.","journal-title":"Blood"},{"issue":"16_suppl","key":"1427_CR27","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1200\/JCO.2022.40.16_suppl.7035","volume":"40","author":"L Zhao","year":"2022","unstructured":"Zhao L, Pan J, Tang K, Tan Y, Deng B, Ling Z, et al. (2022) Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia\/lymphoma. J Clin Oncol. 2022;40(16_suppl):7035\u20137035.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01427-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T07:06:17Z","timestamp":1680678377000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01427-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01427-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board in Beijing Gobroad Boren Hospital gave its approval to the study. All participants in this clinical trial provided voluntary consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed voluntary consent form was obtained from the subjects for publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AHC is a founding member of Shanghai YaKe Biotechnology Ltd., a biotechnology company focused on research and development of tumor cellular immunotherapy. YZ and SP are also employees of Shanghai YaKe Biotechnology Ltd. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}